A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
10/2011
10/05/2011	EP2371393A1 Preventive or remedy for inflammatory disease
10/05/2011	EP2371392A1 Calicheamicin derivative-carrier conjugates
10/05/2011	EP2371374A1 Soluble fiber from Musa spp. for treating gastroenteritis or diarrhea
10/05/2011	EP2371369A1 EGFR inhibitor and antiviral agent for simultaneous, separate or sequential use in the treatment and/or prevention and/or palliation of cancer
10/05/2011	EP2371367A1 Method of treating men with testosterone supplement and 5alpha reductase inhibitor
10/05/2011	EP2371361A1 Methods to mobilize progenitor/stem cells
10/05/2011	EP2371350A1 Foam formulas for treating animal skin illnesses
10/05/2011	EP2370103A2 Pharmaceutical combinations comprising a pyrido[4,3-d]pyrimidine derived hsp90-inhibitor and a her2 inhibitor
10/05/2011	EP2370076A2 Pharmaceutical combination comprising a hsp 90 inhibitor and a mtor inhibitor
10/05/2011	EP1651224B1 Medicaments for inhalation comprising an anticholinergic and a betamimetic
10/05/2011	EP1562577B1 Acetyl-l-carnitine for the prevention and/or treatment of peripheral neuropathies induced by thalidomide
10/05/2011	EP1510216B1 Antithrombogenic ceramic composition and article containing the same
10/05/2011	EP1501830B1 7-aryl-3,9-diazabicyclo[3.3.1]non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases
10/05/2011	EP1463497B1 Treating muscle wasting with selective androgen receptor modulators
10/05/2011	EP1406633B1 Enhanced drug delivery in transdermal systems
10/05/2011	EP1395279B1 Use of neublastin polypeptides for treating neuropathic pain
10/05/2011	EP1377276B1 Timed pulse release composition
10/05/2011	EP1295607B9 Antitumor effect potentiators
10/05/2011	EP1257248B1 Pharmaceutical composition
10/05/2011	EP1069883B1 Self-tanning compositions comprising cholesterol sulphate and DHA
10/05/2011	EP1017835B1 Cytochrome p450 reductase for the enhancement of p450-based anti-cancer gene therapy
10/05/2011	CN1669537B Local vascular delivery of trichostatin A alone or in combination with sirolimus to prevent restenosis following vascular injury
10/05/2011	CN1617704B Composition comprising at least one oxazolin for inhibiting langerhans cell migration, and uses thereof
10/05/2011	CN1446227B Novel fibroblast growth factor (FRF23) and method for use
10/05/2011	CN102209539A P70 s6 kinase inhibitor and mtor inhibitor combination therapy
10/05/2011	CN102209538A P70 s6 kinase inhibitor and egfr inhibitor combination therapy
10/05/2011	CN102206277A Antibodies that bind human interleukin-18 and methods of making and using
10/05/2011	CN102206276A Humanized antibodies derived from DD-3B6/22, specific for the D-dimer fragment of fibrin
10/05/2011	CN102206247A Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
10/05/2011	CN102205127A Administration of capsaicinoids
10/05/2011	CN102205126A Application of combined catechin matters together with antibacterial agents
10/05/2011	CN102205125A Method for making human pelvic inflammation simulating animal model
10/05/2011	CN102205124A Composition for inhibition of expression of miR-27b, medicines containing the same, and use for the same
10/05/2011	CN102204898A Method for inducing ovulation by using non-polypeptide cyclic adenosine 3',5'-monophosphate (cAMP) level modulator
10/05/2011	CN101444470B Use of oligosaccharides to stimulate beta-endorphin production
10/05/2011	CN101380464B Method for treating a movement disorder
10/04/2011	US8030471 Plasmodium malariae and Plasmodium ovale genes and uses thereof
10/04/2011	US8030462 Immunotherapy; induce immunology response
10/04/2011	US8030312 Administering therapeutically effective amount of a carbostyril derivative compound for therapy of nervous system disorders
10/04/2011	US8030296 Oestrogen-17-sulphamates as inhibitors of steroid sulphatase
10/04/2011	US8030294 Cytosine-containing or cytidine-containing compound, creatine-containing compound, adenosine-containing, or adenosine-elevating compound
10/04/2011	US8030287 DNA vaccine against North American spring viremia of carp virus
10/04/2011	US8030285 Asthma; ellergy vaccine; antisense therapy; used to treat, prevent, or ameliorate the symptoms resulting from exposure to a bio-warfare agent
10/04/2011	US8030275 Methods for treating obesity using fibroblast growth factor-like polypeptides
10/04/2011	US8029819 Pet food includes 35-70% by weight protein, 4-10% by weight fat, 5-25% by weight fiber, 10-35% by weight digestible carbohydrate, 0.1-1% by weight functional ingredient to build lean muscle mass
10/04/2011	US8029810 Water-based delivery systems
10/04/2011	US8029809 Bacteriocins and novel bacterial strains
10/04/2011	US8029808 Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
10/04/2011	US8029776 Cationic lipid-mediated enhancement of nucleic acid immunization of cats
10/04/2011	US8029772 Free-flowing anionic surfactant, alkanolamide and electrolytemixture
10/04/2011	US8029768 pharmaceutical composition for pulmonary delivery comprises glycopyrrolate in a controlled release formulation, wherein, on administration, the glycopyrrolate exerts its pharmacological effect over a period greater than 12 hours.
10/04/2011	US8029755 particulate tricalcium phosphate (TCP) having an average particle size of about 5 mu m or less, an average crystal size of about 250 nm or less and a surface area of about 20 m2/g or greater;
10/04/2011	US8029561 Drug combination useful for prevention of restenosis
10/04/2011	CA2642508C Method of removal of hyperplastic skin lesions
10/04/2011	CA2620274C Methods for the treatment of senile dementia of the alzheimer's type
10/04/2011	CA2589059C Trace elements
10/04/2011	CA2480308C Antisense iap nucleobase oligomers and uses thereof
10/04/2011	CA2434773C Piperazinylcarbonylquinolines and -isoquinolines
10/04/2011	CA2245702C Human cancer antigen of tyrosinase-related protein 1 and 2 and genes encoding same
09/2011
09/29/2011	WO2011119288A2 Multilayer melt-extruded film
09/29/2011	WO2011119047A1 Carvacrol/thymol composition for the treatment of salmonid rickettsial septicemia and infectious salmon anemia
09/29/2011	WO2011118779A1 Pharmaceutical composition for treatment and prevention of herpesvirus infections
09/29/2011	WO2011118481A1 Method for reducing unpleasant taste
09/29/2011	WO2011118468A1 Wake-time-extending agent
09/29/2011	WO2011073981A3 Betahistine in compositions and methods for treating somnolence
09/29/2011	WO2011031301A3 Intrapericardial delivery of periostin
09/29/2011	US20110238003 Method for systemic drug delivery through the nail
09/29/2011	US20110237858 Device and Methods for Sequential, Regional Delivery of Multiple Cytotoxic Agents and Directed Assembly of Wound Repair Tissues
09/29/2011	US20110237783 Hydrazonopyrazole derivatives and their use as therapeutics
09/29/2011	US20110237688 Methods and compositions related to acetylocholine receptor conjugates
09/29/2011	US20110237546 Method for treating a mammal by administration of a compound having the ability to release co
09/29/2011	US20110237512 Methods for Treating Bleeding Disorders Using Sulfated Polysaccharides
09/29/2011	US20110236382 Immunosuppressive combination and its use in the treatment or prophylaxis of insulin-producing cell graft rejection
09/29/2011	US20110236365 Method for protecting and treating at least one muscarinic receptor from dysfunction resulting from free radical damage
09/29/2011	CA2794480A1 Carvacrol/thymol composition for the treatment of salmonid rickettsial septicemia and infectious salmon anemia
09/28/2011	EP2369516A2 Methods and apparatuses for assuring quality and safety of drug administration and medical products and kits
09/28/2011	EP2368910A1 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
09/28/2011	EP2368901A1 Peptidomimetic protease inhibitors
09/28/2011	EP2368878A1 Peptidomimetic protease inhibitors
09/28/2011	EP2368877A1 Chiral intermediates for the preparation of peptidomimetic protease inhibitors
09/28/2011	EP2368554A1 Pharmaceutical formulations containing methylnaltrexone
09/28/2011	EP2368553A1 Pharmaceutical formulations containing methylnaltrexone
09/28/2011	EP2368431A1 Immunostimulatory G,U-containing oligoribonucleotides
09/28/2011	EP2367551A1 S1p lyase inhibitors for the treatment of cerebral malaria
09/28/2011	EP2367550A1 Il-3 inhibitors in use for treatment of rheumatoid arthritis in an early stage
09/28/2011	EP2367425A1 Combinations and modes of administration of therapeutic agents and combination therapy
09/28/2011	EP2367422A1 Enema formulations
09/28/2011	EP1643999B1 Pyridoxamine for use in the treatment of diabetic neprhopathy in type ii diabetes
09/28/2011	EP1567014B1 Rapid one-step method for generation of antigen loaded dendritic cell vaccine from precursors
09/28/2011	EP1463531B1 Methods for inhibiting ocular processes
09/28/2011	EP1420800B1 Modulation of insulin-regulated aminopeptidase (irap)/angiotensin iv (at 4) receptor activity
09/28/2011	EP1322307B1 Methods for treating cell proliferative disorders and viral infections
09/28/2011	EP1237891B1 Heterocyclic dihydropyrimidines as potassium channel inhibitors
09/28/2011	CN1543356B Anti-tumor agent
09/28/2011	CN1344159B Combinations for treatment of diseases involving angiogenesis
09/28/2011	CN102203268A Siderophore-mediated iron uptake in bacterial infection
09/28/2011	CN102202667A Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
09/28/2011	CN102202662A Agent for treatment of diabetes
09/28/2011	CN102199656A Method and reagent for regulating and controlling development and transformation of bone marrow
09/28/2011	CN102198272A Medicinal composition for promoting fracture union and repairing injured nerves

1 ... 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 ... 1151